Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Nutrien Ltd (NTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Nutrien Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Nutrien Ltd trades at $65.84 (market cap $31.29B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Nutrien Ltd pays a 3.36% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | NTR | |
|---|---|---|
Market Cap | $39.89B | $31.29B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $83.94 |
52-Week Low | $278.09 | $53.64 |
Enterprise Value | $38.15B | $44.46B |
Dividend Yield | — | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Nutrien (NTR) trades at $65.43, up 1.33% today, with a neutral technical signal and strong analyst consensus. Recent Q1 2026 earnings beat expectations, driven by record potash volumes. The stock shows solid fundamentals with a P/E of 13.33 and ROE of 9.7%, though revenue has declined from 2022 peaks. A dividend of $0.55 per share is scheduled for July 2026, supporting income appeal.
Outlook remains positive with a consensus price target of $80.14, reflecting 22% upside potential. Risks include volatile fertilizer prices and geopolitical impacts on agriculture markets. Institutional sentiment is bullish, with 64% of analysts rating it Buy, but investors should monitor debt levels and global demand shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
